An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul.

Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525

Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data.

ECHELON-1 - Hodgkin's (A+AVD vs. ABVD)

POLO - Pancreatic (olaparib maintenance vs. placebo)

Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo)

APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab)

E1912 - CLL (ibrutinib/rituximab vs. FCR)

Discussion with a Lupus Nephritis patient (and Pharm.D. student) about manifestations and treatments of SLE and Lupus Nephritis.

Sifting through and summarizing lots of data on concomitant use of ICIs and PPIs.

Suggested readings:

1. All the drugs: https://pubmed.ncbi.nlm.nih.gov/33154150/

2. Pooled atezolizumab study: https://pubmed.ncbi.nlm.nih.gov/35183773/

3. Clostridium butyricum may be a thing: https://pubmed.ncbi.nlm.nih.gov/35655708/

4. AKI risk: https://doi.org/10.21873/invivo.12570

5. Is this all noise?: https://pubmed.ncbi.nlm.nih.gov/35280736/

6. Abx & PPIs: https://doi.org/10.3389/fimmu.2021.716317

Acetaminophen (or paracetamol) & immune checkpoint inhibitors are ubiquitous in oncology practices. So, when new translational research suggests APAP may decrease the effectiveness - well that seems like something worth talking about.

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients: https://doi.org/10.1016/j.annonc.2022.05.010

Hepatotoxicity risk factors with ICIs: https://doi.org/10.1097/cji.0000000000000347

Febrile neutropenia updates on...

Short duration antibiotics: https://doi.org/10.1016/S2352-3026(22)00145-4

Same-day pegfilgrastim: https://doi.org/10.2217/fon-2022-0365

Maya Leiva, PharmD, BCOP joins the Pod once again this Pride month to give us some LGBTQ clinical pearls on carboplatin dosing in trans patients and pregnancy/teratogenicity chemo counseling.

LGBT Cancer Network: https://cancer-network.org

Highlights from ASCO's 2022 annual meeting.

Maya Leiva, PharmD, BCOP joins the Pod for Pride to give an overview of cancer screenings in the transgender population.

Looking at some interesting articles as possible predictors of what to expect next in NSCLC and AML.

NADIM: https://pubmed.ncbi.nlm.nih.gov/?term=35576508

Ven + Intensive Chemo: https://doi.org/10.1016/S2352-3026(22)00100-4